CGTLive’s Weekly Rewind – January 5, 2024


Review top news and interview highlights from the week ending January 5, 2024.

CGTLive’s Weekly Rewind – January 5, 2024

CGTLive’s Weekly Rewind – January 5, 2024

Welcome to CGTLive™’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.

1. After Exa-Cel: Exploring the Next Wave of CRISPR Gene Editing Strategies

The approval of exa-cel, the first gene editing therapy, may herald a new era in developing gene editing strategies.

2. Alexis Thompson, MD, MPH, on the Simultaneous Approvals of Exa-cel and Lovo-cel For SCD

The chief of hematology at Children’s Hospital of Philadelphia discussed dual approval of the 2 gene therapies that coincided with ASH’s 2023 conference.

3. Pfizer’s Hemophilia B Gene Therapy Approved as Beqvez in Canada

The FDA and EMA have accepted marketing authorization applications and decisions are pending.

4. Piers Blombery, MBBS, PhD, on Looking Deeper Into Effects of CAR T After CAR+ Lymphoma

The associate professor at Peter MacCallum Cancer Centre discussed further research and questions that need to be investigated with the cell therapy.

5. Oncternal Therapeutics Proposes Protocol Changes Following Death of Patient Treated With CAR-T Therapy ONCT-808 in Phase 1/2 Trial

ONCT-808 targets ROR1 and is currently being evaluated for the treatment of r/r aggressive B-cell lymphoma.

Related Videos
Alexandra Gomez Arteaga, MD
Mark Walters, MD
Mitchel Horwitz, MD
Emilie Aschenbrenner, PharmD, BCOP, a hematology coordinator for pharmacy at Froedtert and the Medical College of Wisconsin
Jessica S. Little, MD, a transplant infectious diseases physician at Dana-Farber Cancer Institute
Nirav N. Shah, MD
Alexis Kuhn, PharmD, BCOP, a pediatric oncology pharmacist at the Mayo Clinic
Haydar Frangoul, MD
Aimee C. Talleur, MD, a physician at St. Jude Children’s Research Hospital
© 2024 MJH Life Sciences

All rights reserved.